UroGen Pharma - URGN Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UroGen Pharma in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" URGN shares.
View URGN analyst ratings or view top-rated stocks.

3 equities research analysts have issued 12 month price objectives for UroGen Pharma's stock. Their URGN share price forecasts range from $11.00 to $26.00. On average, they predict the company's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 122.7% from the stock's current price.
View analysts price targets for URGN or view top-rated stocks among Wall Street analysts.

UroGen Pharma's stock was trading at $9.51 at the start of the year. Since then, URGN stock has decreased by 10.3% and is now trading at $8.53.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our URGN earnings forecast.

UroGen Pharma Ltd. (NASDAQ:URGN) released its earnings results on Monday, November, 15th. The company reported ($1.35) EPS for the quarter, missing the consensus estimate of ($1.26) by $0.09. The business had revenue of $11.35 million for the quarter, compared to analyst estimates of $15.90 million. UroGen Pharma had a negative trailing twelve-month return on equity of 572.49% and a negative net margin of 209.30%. During the same period in the prior year, the company posted ($1.31) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other UroGen Pharma investors own include Sorrento Therapeutics (SRNE), Micron Technology (MU), OPKO Health (OPK), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL), (KITE) (KITE), Syndax Pharmaceuticals (SNDX), AbbVie (ABBV) and Aytu BioPharma (AYTU).

(URGN) raised $46 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 3,500,000 shares at $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

UroGen Pharma trades on the NASDAQ under the ticker symbol "URGN."

UroGen Pharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Menora Mivtachim Holdings LTD. (14.11%), Credit Suisse AG (0.00%), Wells Fargo & Company MN (1.87%), ARK Investment Management LLC (1.45%), Cerity Partners LLC (0.60%) and Rice Hall James & Associates LLC (0.53%). Insiders that own company stock include Elizabeth A Barrett, Jason Drew Smith, Mark Schoenberg, Molly Henderson, Peter P Pfreundschuh and Stephen Mullennix.
View institutional ownership trends.

Shares of URGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of URGN stock can currently be purchased for approximately $8.53.

UroGen Pharma (NASDAQ:URGN) has a market capitalization of $178.28 million and generates $48.04 million in revenue each year. The company earns $-110,820,000.00 in net income (profit) each year or ($5.04) on an earnings per share basis.

The company employs 195 workers across the globe.

UroGen Pharma's mailing address is 400 Alexander Park, Princeton NJ, 08540. The official website for the company is www.urogen.com. The company can be reached via phone at (646) 768-9780 or via email at kate.bechtold@urogen.com.